The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial demonstrated no mortality benefit for annual PSA screening after 13 years of follow-up.17 However, this trial was intrinsically flawed, with nearly 90% controls undergoing PSA screening19 and no mandated biopsy or treatment for an elevated PSA level. The gene discussed is KLK3; the disease is ovarian carcinoma.